These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35948584)

  • 41. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE.
    Doycheva I; Cui J; Nguyen P; Costa EA; Hooker J; Hofflich H; Bettencourt R; Brouha S; Sirlin CB; Loomba R
    Aliment Pharmacol Ther; 2016 Jan; 43(1):83-95. PubMed ID: 26369383
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
    Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel 3D Magnetic Resonance Elastography for the Noninvasive Diagnosis of Advanced Fibrosis in NAFLD: A Prospective Study.
    Loomba R; Cui J; Wolfson T; Haufe W; Hooker J; Szeverenyi N; Ang B; Bhatt A; Wang K; Aryafar H; Behling C; Valasek MA; Lin GY; Gamst A; Brenner DA; Yin M; Glaser KJ; Ehman RL; Sirlin CB
    Am J Gastroenterol; 2016 Jul; 111(7):986-94. PubMed ID: 27002798
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease.
    Wong VW; Irles M; Wong GL; Shili S; Chan AW; Merrouche W; Shu SS; Foucher J; Le Bail B; Chan WK; Chan HL; de Ledinghen V
    Gut; 2019 Nov; 68(11):2057-2064. PubMed ID: 30658997
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Transient Versus Two-Dimensional Shear-Wave Elastography in a Multistep Strategy to Detect Advanced Fibrosis in NAFLD.
    Cassinotto C; Boursier J; Paisant A; Guiu B; Irles-Depe M; Canivet C; Aube C; de Ledinghen V
    Hepatology; 2021 Jun; 73(6):2196-2205. PubMed ID: 33236409
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Magnetic resonance elastography measured shear stiffness as a biomarker of fibrosis in pediatric nonalcoholic fatty liver disease.
    Schwimmer JB; Behling C; Angeles JE; Paiz M; Durelle J; Africa J; Newton KP; Brunt EM; Lavine JE; Abrams SH; Masand P; Krishnamurthy R; Wong K; Ehman RL; Yin M; Glaser KJ; Dzyubak B; Wolfson T; Gamst AC; Hooker J; Haufe W; Schlein A; Hamilton G; Middleton MS; Sirlin CB
    Hepatology; 2017 Nov; 66(5):1474-1485. PubMed ID: 28493388
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Non-alcoholic fatty liver disease and periodontal disease: A systematic review and meta-analysis of cross-sectional studies.
    Aguiar ILS; Santos-Lins LS; Brasil-Oliveira R; Cotrim HP; Lins-Kusterer L
    Arab J Gastroenterol; 2023 Nov; 24(4):198-203. PubMed ID: 37993376
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of PERIOdontal treatment versus usual care for Nonalcoholic liver disease: protocol of the PERION multicenter, two-arm, open-label, randomized trial.
    Kamata Y; Kessoku T; Shimizu T; Kobayashi T; Kurihashi T; Sato S; Kuraji S; Aoyama N; Iwasaki T; Takashiba S; Hamada N; Kodama T; Tamura T; Ino S; Higurashi T; Taguri M; Yamanaka T; Yoneda M; Usuda H; Wada K; Nakajima A; Minabe M
    Trials; 2020 Mar; 21(1):291. PubMed ID: 32293522
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis.
    Jung J; Loomba RR; Imajo K; Madamba E; Gandhi S; Bettencourt R; Singh S; Hernandez C; Valasek MA; Behling C; Richards L; Fowler K; Sirlin CB; Nakajima A; Loomba R
    Gut; 2021 Oct; 70(10):1946-1953. PubMed ID: 33214165
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography.
    Tapper EB; Sengupta N; Hunink MG; Afdhal NH; Lai M
    Am J Gastroenterol; 2015 Sep; 110(9):1298-304. PubMed ID: 26303130
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prediction of nonalcoholic fatty liver disease (NAFLD) activity score (NAS) with multiparametric hepatic magnetic resonance imaging and elastography.
    Yin Z; Murphy MC; Li J; Glaser KJ; Mauer AS; Mounajjed T; Therneau TM; Liu H; Malhi H; Manduca A; Ehman RL; Yin M
    Eur Radiol; 2019 Nov; 29(11):5823-5831. PubMed ID: 30887196
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Non-invasive tests of non-alcoholic fatty liver disease.
    Li G; Zhang X; Lin H; Liang LY; Wong GL; Wong VW
    Chin Med J (Engl); 2022 Jan; 135(5):532-546. PubMed ID: 35089884
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Magnetic resonance elastography in staging liver fibrosis in non-alcoholic fatty liver disease: a pooled analysis of the diagnostic accuracy.
    Liang Y; Li D
    BMC Gastroenterol; 2020 Apr; 20(1):89. PubMed ID: 32252641
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease.
    Nakahara T; Hyogo H; Ono A; Nagaoki Y; Kawaoka T; Miki D; Tsuge M; Hiraga N; Hayes CN; Hiramatsu A; Imamura M; Kawakami Y; Aikata H; Ochi H; Abe-Chayama H; Furusho H; Shintani T; Kurihara H; Miyauchi M; Takata T; Arihiro K; Chayama K
    J Gastroenterol; 2018 Feb; 53(2):269-280. PubMed ID: 28741270
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Estimating steatosis and fibrosis: Comparison of acoustic structure quantification with established techniques.
    Karlas T; Berger J; Garnov N; Lindner F; Busse H; Linder N; Schaudinn A; Relke B; Chakaroun R; Tröltzsch M; Wiegand J; Keim V
    World J Gastroenterol; 2015 Apr; 21(16):4894-902. PubMed ID: 25945002
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD.
    Tapper EB; Loomba R
    Nat Rev Gastroenterol Hepatol; 2018 May; 15(5):274-282. PubMed ID: 29463906
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Free Triiodothyronine Is Associated With Hepatic Steatosis and Liver Stiffness in Euthyroid Chinese Adults With Non-Alcoholic Fatty Liver Disease.
    Guo W; Qin P; Li XN; Wu J; Lu J; Zhu WF; Diao QQ; Xu NZ; Zhang Q
    Front Endocrinol (Lausanne); 2021; 12():711956. PubMed ID: 34456869
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Liver fibrosis screening, evaluation pathway, and management in patients with fatty liver].
    Xu L; Mi YQ
    Zhonghua Gan Zang Bing Za Zhi; 2023 Aug; 31(8):798-804. PubMed ID: 37723060
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Increased severity of liver fat content and liver fibrosis in non-alcoholic fatty liver disease correlate with epicardial fat volume in type 2 diabetes: A prospective study.
    Brouha SS; Nguyen P; Bettencourt R; Sirlin CB; Loomba R
    Eur Radiol; 2018 Apr; 28(4):1345-1355. PubMed ID: 29058029
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD).
    Han MA; Saouaf R; Ayoub W; Todo T; Mena E; Noureddin M
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):379-390. PubMed ID: 28277807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.